Retinoic acid receptor alpha, beta, and gamma; Retinoid X receptor alpha, beta, and gamma (RAR-α, RAR-β, RAR-γ; RXR-α, RXR-β, RXR-γ)

Retinoic acid receptors (RAR-alpha, beta, and gamma) and retinoid X receptors (RXR-alpha, beta, and gamma) are families of nuclear receptor transcription factors that mediate the effects of vitamin A derivatives (retinoids) by regulating the expression of genes involved in cell differentiation, proliferation, and metabolic processes. They function as ligand-activated transcription factors, forming heterodimers (typically RAR/RXR) that bind to retinoic acid response elements (RAREs) on DNA. Upon ligand binding (e.g., all-trans retinoic acid for RARs, 9-cis retinoic acid for RXRs), these complexes regulate chromatin architecture and transcriptional activity by recruiting coactivators or releasing corepressors. These receptors are essential in embryogenesis, immune regulation, and maintenance of epithelial tissues and are clinically significant in oncology (notably acute promyelocytic leukemia and other cancers), dermatology, and metabolic diseases[1][2][3][4][5][6][7]. Therapies targeting RAR and RXR have profound effects but require careful management due to teratogenic and metabolic toxicities.

Other names

RAR-alpha (RARA), RAR-beta (RARB), RAR-gamma (RARG)RXR-alpha (RXRA), RXR-beta (RXRB), RXR-gamma (RXRG)Retinoic acid receptorRetinoid X receptorNuclear receptor subfamily 1 group B members (RARs)Nuclear receptor subfamily 2 group B members (RXRs)Retinoid receptors

Agonists/antagonists bind to ligand-binding domain, altering receptor’s association with coactivators/corepressors and affecting transcription of retinoic acid response element (RARE)–containing genes[2][3][7]. Heterodimerization with RXRs or RARs facilitates transcriptional activation or repression[1][2][4][5].